Shigeru Takahashi

Ono Pharmaceutical (Japan) — Japan

Medicine · Health Sciences

35h-index5.3kcitations337works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neonatal Respiratory Health Research(29), Salivary Gland Disorders and Functions(27), Bone and Dental Protein Studies(20), Gastric Cancer Management and Outcomes(18), dental development and anomalies(17)

Publications337 total

Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC)
Future Oncology·2026
Four‐Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous <scp>NSCLC</scp> in the <scp>TASUKI</scp> ‐52
Cancer Science·2026Open Access
Clinical Significance of Phase Angle for Assessing Quality of Life and Prognosis in Hemodialysis Patients
Nutrients·2025Open Access
Distribution and possible function of transient receptor potential melastatin-7 in the rat cranial sensory ganglia
Biomedical Research·2025Open Access
Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025Open Access
Figure 3 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025Open Access
Table 3 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025Open Access
Data from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025Open Access
Table 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025Open Access
Table 4 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025Open Access
Table 2 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025Open Access
Figure 2 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025Open Access
Supplemental Table 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025Open Access
Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
Cancer Research Communications·2025Open Access
An Extended Closure Relation by LightGBM for Neutrino Radiation Transport in Core-collapse Supernovae
The Astrophysical Journal·2025· 1 citedOpen Access
Association Between Malnutrition, Low Muscle Mass, Elevated NT-ProBNP Levels, and Mortality in Hemodialysis Patients
Nutrients·2025· 1 citedOpen Access
Recolorable Graph Exploration by an Oblivious Agent with Fewer Colors
DROPS (Schloss Dagstuhl – Leibniz Center for Informatics)·2025Open Access
Effect of SGLT2 inhibitors on temporal change of skeletal muscle index in patients with outpatient cardiac rehabilitation program
European Journal of Preventive Cardiology·2025Open Access
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor- and Metformin-Associated Euglycemic Diabetic Ketoacidosis and Lactic Acidosis Leading to Refractory Acute Kidney Injury: Successful Management With Hemodialysis
Cureus·2025· 2 citedOpen Access
Association of Ankle–Brachial Index with Quality of Life and Survival Outcomes in Hemodialysis Patients
Journal of Clinical Medicine·2025Open Access
page 1 of 17Next →

Frequent Co-authors

Yûji Takahashi(11), Shigeharu Hosono(11), Hideo Mugishima(9), Tsuneyuki Yamamoto(7), Michiyoshi Minato(7), Takashi Miura(6), Hidetoshi Fujita(6), Tomoo Okada(6), T. Domon(6), M. Wakita(6), Akiyoshi Fukamizu(5), Naoki Masaoka(5), Ikuhiro Inami(5), Masami Makimoto(5), Shiro Nakamura(4), Kazuo Murakami(4), Kensuke Harada(4), Tatsuo Yamamoto(4), Hiroshi Asahara(3), Etsurou Bandou(3)